Evidence map›Paper›PMID 26305236›Full record

ReviewSeminars in thrombosis and hemostasis2015

Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.

Nivetha Murugesan, Tuna Üstunkaya, Edward P Feener

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in thrombosis and hemostasis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Targeting NLRP3/caspase-1/GSDMD to treat inner ear injury from labyrinthine hemorrhage.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Nivetha MurugesanSection on Vascular Cell Biology, Research Division, Joslin Diabetes Center, Boston, Massachusetts.
Tuna ÜstunkayaHacettepe University Medical School, Ankara, Turkey.
Edward P FeenerSection on Vascular Cell Biology, Research Division, Joslin Diabetes Center, Boston, Massachusetts.
Hacettepe University · TRHarvard University · USJoslin Diabetes Center · US

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
Training Program in the Molecular Bases of Eye DiseasesT32EY007145 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore, MEREDITH GREGORY-KSANDER · 1997 to 2026
$4.5M
Role of the kallikrein-kinin system in diabetic retinopathyR01EY019029 · NEI · JOSLIN DIABETES CENTER · PI AIELLO, LLOYD P · 2008 to 2017
$3.8M
NEI NIH HHS EY019029NEI NIH HHS R01 EY019029NEI NIH HHS T32 EY007145NEI NIH HHS T32EY007145NIDDK NIH HHS DK36836NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

Retinal ischemia and hemorrhage are hallmarks of worsening diabetic retinopathy, which can lead to neovascularization, macular edema, and severe vision loss. Although diabetes alters expression of clotting factors and their activities, and increases retinal microthromboses, the effects of thrombotic processes on the pathogenesis of diabetic retinopathy are not fully understood. In addition to the roles of coagulation and fibrinolytic cascades in thrombosis and hemostasis, components in these systems also mediate multiple effects on the vasculature that promote inflammation. Plasma kallikrein, thrombin, and urokinase are increased in diabetic retinopathy, and exert proinflammatory effects that contribute to retinal vascular dysfunction. The accumulation and activation of these and additional coagulation factors in the vitreous due to hemorrhage and chronic retinal injury in the diabetic retina may contribute to worsening of retinal inflammation and capillary dysfunction, which lead to retinal ischemia and edema. Further understanding of the role for specific coagulation factors in diabetic retinopathy may suggest new therapeutic opportunities for this vision-threatening disease.

Indexed as

Anti-Inflammatory AgentsBlood Coagulation FactorsCapillary PermeabilityCytokinesDiabetic RetinopathyDisease ProgressionHumansInflammationIschemiaMicrocirculationModels, BiologicalRetinal HemorrhageRetinal NeovascularizationRetinal Vein OcclusionRetinal VesselsThrombophiliaAnti-Inflammatory AgentsBlood Coagulation FactorsCytokines

Identifiers

PMID26305236
PMCPMC4765320
OpenAlexW1835870821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.